Condition: Disease Bowel · Crohn Disease · Ulcerative Colitis · Sponsor: Hospices Civils de Lyon
Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients. Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares. The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare. Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.
This description comes directly from the study's public registry record.
Gilles Boschetti, MD,PhD · +33 4 78 86 13 02 · gilles.boschetti@chu-lyon.fr
Maelys Cheviakoff · +33 4 78 86 37 66 · maelys.cheviakoff01@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| CHU Clermont-Ferrand, Hôpital d'Estaing | Clermont-Ferrand, France | Not Yet Recruiting |
| CHU Grenoble Hôpital Michallon-Site Nord | Grenoble, France | Not Yet Recruiting |
| Lyon Sud hospital | Pierre-Bénite, France | Recruiting |
| CHU Saint Etienne | Saint-Etienne, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05835973